Ring, Sandra S.
Cupovic, Jovana
Onder, Lucas
Lütge, Mechthild http://orcid.org/0000-0001-9011-5319
Perez-Shibayama, Christian
Gil-Cruz, Cristina
Scandella, Elke
De Martin, Angelina
Mörbe, Urs http://orcid.org/0000-0001-8747-437X
Hartmann, Fabienne http://orcid.org/0000-0003-2247-2693
Wenger, Robert
Spiegl, Matthias http://orcid.org/0000-0003-3940-7791
Besse, Andrej
Bonilla, Weldy V.
Stemeseder, Felix
Schmidt, Sarah
Orlinger, Klaus K.
Krebs, Philippe http://orcid.org/0000-0003-4918-6654
Ludewig, Burkhard http://orcid.org/0000-0002-7685-573X
Flatz, Lukas
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (166500, 159188, 157448, 187189)
Article History
Received: 9 December 2020
Accepted: 19 July 2021
First Online: 5 August 2021
Competing interests
: The authors declare the following competing interests. L.F. is a founder and shareholder of Hookipa Pharma Inc. F.S., S.S., and K.K.O. are employees and stock option holder of Hookipa Pharma, Inc. L.F., S.S.R, S.S., and K.K.O are listed as inventors of the patent entitled “Arenavirus particles to treat solid tumors” (patent number WO2018/185307 A1) describing the application of artLCMV vectors in the treatment of tumors. B.L., L.O., C.P.S., and C.G.C. are founders and shareholders of Stromal Therapeutics AG. S.S.R. is part-time employee of Stromal Therapeutics AG. The remaining authors declare no competing interests.